We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

133 hedge funds and large institutions have $1.1B invested in Lexicon Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 36

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3% less funds holding

Funds holding: 137 → 133 (-4)

3.16% less ownership

Funds ownership: 108.74% → 105.58% (-3.2%)

14% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 28

17% less call options, than puts

Call options by funds: $1.11M | Put options by funds: $1.33M

22% less capital invested

Capital invested by funds: $1.41B → $1.1B (-$309M)

Holders
133
Holders Change
-4
Holders Change %
-2.92%
% of All Funds
3.02%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
24
Increased
39
Reduced
36
Closed
28
Calls
$1.11M
Puts
$1.33M
Net Calls
-$225K
Net Calls Change
+$12.2M

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$7.86M
2
UBS AM
UBS AM
Illinois
+$6.06M
3
CLM
ClearBridge LLC (Maryland)
Maryland
+$3.26M
4
TCM
Tekla Capital Management
Massachusetts
+$2.9M
5
State Street
State Street
Massachusetts
+$2.53M

Top Sellers

Rank Fund Capital Flow
1
EAM
Eagle Asset Management
Florida
-$34.5M
2
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$12.1M
3
KCM
Kornitzer Capital Management
Kansas
-$9.42M
4
CCI
Columbus Circle Investors
-$5.14M
5
BlackRock
BlackRock
New York
-$4.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$2.17M +$160K +15,428 +8%
DekaBank Deutsche Girozentrale
27
DekaBank Deutsche Girozentrale
Germany
$2.08M – – –
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.98M -$29.8K -2,869 -1%
Two Sigma Investments
29
Two Sigma Investments
New York
$1.74M +$662K +63,672 +57%
Bank of America
30
Bank of America
North Carolina
$1.71M -$4.66M -448,230 -72%
Citadel Advisors
31
Citadel Advisors
Florida
$1.67M +$1.09M +105,068 +164%
Jacobs Levy Equity Management
32
Jacobs Levy Equity Management
New Jersey
$1.42M +$1.5M +144,139 New
WS
33
Wedbush Securities
California
$1.37M +$279K +26,873 +24%
Goldman Sachs
34
Goldman Sachs
New York
$1.33M -$1.14M -110,094 -45%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$1.16M – – –
UBS Group
36
UBS Group
Switzerland
$1.11M -$479K -46,115 -29%
Morgan Stanley
37
Morgan Stanley
New York
$1.11M +$79.3K +7,628 +7%
JP Morgan Chase
38
JP Morgan Chase
New York
$1.07M +$49.7K +4,785 +5%
TCIM
39
TIAA CREF Investment Management
New York
$992K -$167K -16,025 -14%
VEA
40
Virtus ETF Advisers
New York
$939K +$786K +75,607 +388%
VFA
41
Virtus Fund Advisers
Connecticut
$939K +$988K +95,079 New
Stifel Financial
42
Stifel Financial
Missouri
$893K +$102K +9,859 +12%
Swiss National Bank
43
Swiss National Bank
Switzerland
$791K – – –
Citigroup
44
Citigroup
New York
$770K +$50.6K +4,866 +7%
TA
45
Teachers Advisors
New York
$763K – – –
AllianceBernstein
46
AllianceBernstein
Tennessee
$736K -$1.11M -107,300 -59%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$736K +$195K +18,789 +34%
GCP
48
GSA Capital Partners
United Kingdom
$732K +$242K +23,300 +46%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$671K -$12.2K -1,173 -2%
ProShare Advisors
50
ProShare Advisors
Maryland
$625K +$8.84K +851 +1%
1
2
3 4 5

LXRX Hedge Fund Activity: Q4 2017 in Review

133 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2017, worth a combined $1.1B — down 22% from $1.41B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of LXRX and 24 opened new positions — a net loss of 4 holders — while 36 trimmed existing stakes and 39 added.

The largest buyer was Artal Group, adding an estimated $7.86M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $34.5M sold.

  • 133 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2017, down from 137 in Q3 2017.
  • Funds reported $1.1B of Lexicon Pharmaceuticals stock for Q4 2017, down 22% quarter-over-quarter.
  • 24 funds opened new Lexicon Pharmaceuticals positions in Q4 2017 and 28 closed out, a net change of -4 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q4 2017 was Artal Group, an estimated $7.86M added.
  • The largest Lexicon Pharmaceuticals seller in Q4 2017 was Eagle Asset Management, an estimated $34.5M sold.

Based on aggregated 13F filings for Q4 2017.